A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Seagen Inc.
Compass Therapeutics
BioNTech SE
University of Cincinnati
Astellas Pharma Inc
Providence Health & Services
University of Chicago
PDS Biotechnology Corp.
Groupe Oncologie Radiotherapie Tete et Cou
Washington University School of Medicine
Inhibrx Biosciences, Inc
Thomas Jefferson University
Wake Forest University Health Sciences
Bicara Therapeutics
UNC Lineberger Comprehensive Cancer Center
Dragonfly Therapeutics
PMV Pharmaceuticals, Inc
Hoffmann-La Roche
Tizona Therapeutics, Inc
University of California, San Diego
IDEAYA Biosciences
Merck Sharp & Dohme LLC
University of California, San Diego
UNC Lineberger Comprehensive Cancer Center